Please assess the completion status of the following clinical trial:

Trial Title: Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.~* The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.~* The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.~* The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.~Exclusion Criteria:~* The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.~* The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group (Type: None): No participants received any drug administration. No intervention conducted.

Based on this trial design, predict the completion outcome and termination type (if applicable).